-
2024-516242-19-00
5
2024-11-05
lupus nephritis
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2024-516101-23-00
5
2024-10-28
Sarcoidosis
-
2023-508005-24-00
5
2024-08-01
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2023-509905-62-00
5
2024-07-19
Lower limb trauma requiring immobilisation
-
2023-505112-38-00
11
2024-07-01
recently active non-infectious intermediate, posterior, and pan-uveiti
-
2023-507871-23-00
5
2024-05-27
Relapsed/Refractory Multiple Myeloma
-
2022-501554-11-00
4
2024-03-21
Patients with previously untreated Richter’s syndrome (RS), defined as
-
2023-504366-36-00
5
2024-02-17
de novo acute respiratory failure
-
2022-500862-93-00
5
2024-02-01
Pulmonary Hypertension
-
2022-502741-10-00
7
2024-01-26
Acute Leukemia with Mixed Lineage Leukemia (MLL)-rearrangement or Nucl
-
2023-505911-19-00
4
2024-01-05
Acute Myeloid Leukemia
-
2024-512041-17-00
4
2023-11-27
Patient with non-segmental (symmetrical) vitiligo with a body surface
-
2023-503582-35-00
6
2023-10-26
Staphylococcus aureus bacteremia
-
2022-501710-62-02
6
2023-06-07
Peripheral T-cell lymphoma (PTCL)
-
2024-511866-36-00
5
2023-03-11
patients hospitalized in ICU with ESBL-producing Enterobacteriaceae se
-
2022-500234-29-00
5
2022-11-28
Rheumatoid Arthritis
-
2023-507699-38-00
5
2022-08-30
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2024-515354-24-00
9
2022-05-18
Low risk myelodysplastic syndrom without RS having failed or being ine
-
2024-515945-40-00
10
2022-05-02
Non small cell lung cancer
-
2024-510690-16-00
5
2022-01-31
Relapsed/refractory follicular lymphoma
-
2024-513427-17-00
6
2021-05-20
Well controlled severe allergic asthma
-
2024-514156-33-00
5
2019-08-20
Patients in remission for granulomatosis with polyangiitis (GPA,
Wegen
-
2022-501254-10-00
5
2018-08-24
Advanced tumors